



(51) International Patent Classification:

C07D 311/60 (2006.01) **C07D 417/12** (2006.01)
C07D 405/12 (2006.01) **C07D 417/14** (2006.01)
C07D 407/12 (2006.01) **C07F 9/09** (2006.01)
C07D 407/14 (2006.01) **A61K 31/353** (2006.01)
C07D 409/12 (2006.01) **A61P 9/00** (2006.01)
C07D 413/12 (2006.01)

(21) International Application Number:

PCT/EP2014/054417

(22) International Filing Date:

7 March 2014 (07.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13305263.9 8 March 2013 (08.03.2013) EP

(71) Applicant: **SANOFI** [FR/FR]; 54 rue La Boétie, F-75008 Paris (FR).

(72) **Inventors:** **CZECHTIZKY, Werngard**; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **WESTON, John**; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **RACKELMANN, Nils**; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **KRAFT, Volker**; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **ARNDT, Petra**; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **WIRTH, Klaus**; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **GOEGELEIN, Heinz**; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **RITZELER, Olaf**; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE).

(74) **Agent:** **KUJATH, Eckard**; Sanofi-Aventis Deutschland GmbH, Global Intellectual Property Department, Industriepark Hoechst, Geb. K 703, 65926 Frankfurt am Main (DE).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: SUBSTITUTED CHROMAN-6-YLOXY-CYCLOALKANES AND THEIR USE AS PHARMACEUTICALS



(I)

(57) **Abstract:** The present invention relates to substituted chroman-6-yloxy-cycloalkanes of the formula (I) in which Ar, R1 to R4, p and q are as defined in the claims. The compounds of the formula (I) are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.



WO 2014/135674 A1